{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T05:22:51Z","timestamp":1791868971967,"version":"4.3.4"},"reference-count":130,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,10,14]],"date-time":"2020-10-14T00:00:00Z","timestamp":1602633600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["kireports.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Kidney International Reports"],"published-print":{"date-parts":[[2021,1]]},"DOI":"10.1016\/j.ekir.2020.10.009","type":"journal-article","created":{"date-parts":[[2020,10,20]],"date-time":"2020-10-20T22:49:10Z","timestamp":1603234150000},"page":"11-23","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":111,"title":["Complement in Secondary Thrombotic Microangiopathy"],"prefix":"10.1016","volume":"6","author":[{"given":"Lilian Monteiro Pereira","family":"Palma","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meera","family":"Sridharan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sanjeev","family":"Sethi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ekir.2020.10.009_bib1","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1056\/NEJMra020528","article-title":"Thrombotic microangiopathies","volume":"347","author":"Moake","year":"2002","journal-title":"N\u00a0Engl J Med"},{"issue":"suppl 11","key":"10.1016\/j.ekir.2020.10.009_bib2","first-page":"2","article-title":"Atypical hemolytic uremic syndrome (aHUS): essential aspects of an accurate diagnosis","volume":"14","author":"Laurence","year":"2016","journal-title":"Clin Adv Hematol Oncol"},{"key":"10.1016\/j.ekir.2020.10.009_bib3","doi-asserted-by":"crossref","first-page":"1847","DOI":"10.1056\/NEJMra1312353","article-title":"Syndromes of thrombotic microangiopathy","volume":"371","author":"George","year":"2014","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.ekir.2020.10.009_bib4","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1111\/jth.13571","article-title":"Consensus on the standardization of terminology in thrombotic thrombocytopenic purpura and related thrombotic microangiopathies","volume":"15","author":"Scully","year":"2017","journal-title":"J\u00a0Thromb Haemost"},{"key":"10.1016\/j.ekir.2020.10.009_bib5","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1111\/nep.13234","article-title":"Consensus opinion on diagnosis and management of thrombotic microangiopathy in Australia and New Zealand","volume":"23","author":"Fox","year":"2018","journal-title":"Nephrology (Carlton)"},{"key":"10.1016\/j.ekir.2020.10.009_bib6","doi-asserted-by":"crossref","first-page":"1432","DOI":"10.1056\/NEJM198212023072306","article-title":"Unusually large plasma factor VIII:von Willebrand factor multimers in chronic relapsing thrombotic thrombocytopenic purpura","volume":"307","author":"Moake","year":"1982","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.ekir.2020.10.009_bib7","doi-asserted-by":"crossref","first-page":"1844","DOI":"10.2215\/CJN.02210310","article-title":"Relative role of genetic complement abnormalities in sporadic and familial aHUS and their impact on clinical phenotype","volume":"5","author":"Noris","year":"2010","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.ekir.2020.10.009_bib8","doi-asserted-by":"crossref","first-page":"554","DOI":"10.2215\/CJN.04760512","article-title":"Genetics and outcome of atypical hemolytic uremic syndrome: a nationwide French series comparing children and adults","volume":"8","author":"Fremeaux-Bacchi","year":"2013","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.ekir.2020.10.009_bib9","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1182\/blood-2015-08-663435","article-title":"The genetic fingerprint of susceptibility for transplant-associated thrombotic microangiopathy","volume":"127","author":"Jodele","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.ekir.2020.10.009_bib10","first-page":"347","article-title":"Atypical hemolytic uremic syndrome in the setting of complement-amplifying conditions: case reports and a review of the evidence for treatment with eculizumab","volume":"30","author":"Asif","year":"2017","journal-title":"J\u00a0Nephrol"},{"key":"10.1016\/j.ekir.2020.10.009_bib11","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1016\/j.kint.2018.02.029","article-title":"Clinical and genetic predictors of atypical hemolytic uremic syndrome phenotype and outcome","volume":"94","author":"Schaefer","year":"2018","journal-title":"Kidney Int"},{"key":"10.1016\/j.ekir.2020.10.009_bib12","doi-asserted-by":"crossref","first-page":"e157","DOI":"10.1016\/S2352-3026(17)30026-1","article-title":"Derivation and external validation of the PLASMIC score for rapid assessment of adults with thrombotic microangiopathies: a cohort study","volume":"4","author":"Bendapudi","year":"2017","journal-title":"Lancet Haematol"},{"key":"10.1016\/j.ekir.2020.10.009_bib13","doi-asserted-by":"crossref","first-page":"e4565","DOI":"10.1136\/bmj.e4565","article-title":"Validation of treatment strategies for enterohaemorrhagic Escherichia coli O104:H4 induced haemolytic uraemic syndrome: case\u2013control study","volume":"345","author":"Menne","year":"2012","journal-title":"BMJ"},{"key":"10.1016\/j.ekir.2020.10.009_bib14","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1016\/j.hoc.2015.01.007","article-title":"Shiga toxin associated hemolytic uremic syndrome","volume":"29","author":"Keir","year":"2015","journal-title":"Hematol Oncol Clin North Am"},{"key":"10.1016\/j.ekir.2020.10.009_bib15","doi-asserted-by":"crossref","first-page":"2163","DOI":"10.1007\/s00467-016-3420-7","article-title":"Fecal diagnostics in combination with serology: best test to establish STEC-HUS","volume":"31","author":"Wijnsma","year":"2016","journal-title":"Pediatr Nephrol"},{"key":"10.1016\/j.ekir.2020.10.009_bib16","doi-asserted-by":"crossref","first-page":"2237","DOI":"10.1093\/ndt\/gft198","article-title":"The role of complement in Streptococcus pneumoniae\u2013associated haemolytic uraemic syndrome","volume":"28","author":"Szilagyi","year":"2013","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.ekir.2020.10.009_bib17","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1093\/ndt\/gfw453","article-title":"Eculizumab in secondary atypical haemolytic uraemic syndrome","volume":"32","author":"Cavero","year":"2017","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.ekir.2020.10.009_bib18","doi-asserted-by":"crossref","first-page":"1298","DOI":"10.1016\/j.kint.2019.01.043","article-title":"Secondary atypical hemolytic uremic syndromes in the era of complement blockade","volume":"95","author":"Praga","year":"2019","journal-title":"Kidney Int"},{"key":"10.1016\/j.ekir.2020.10.009_bib19","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/j.tmrv.2019.09.001","article-title":"Clinical complement analysis\u2014an overview","volume":"33","author":"Skattum","year":"2019","journal-title":"Transfus Med Rev"},{"key":"10.1016\/j.ekir.2020.10.009_bib20","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1016\/j.kint.2015.12.003","article-title":"Diagnosis of complement alternative pathway disorders","volume":"89","author":"Angioi","year":"2016","journal-title":"Kidney Int"},{"key":"10.1016\/j.ekir.2020.10.009_bib21","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1055\/s-0034-1375701","article-title":"Pathology of renal diseases associated with dysfunction of the alternative pathway of complement: C3 glomerulopathy and atypical hemolytic uremic syndrome (aHUS)","volume":"40","author":"Sethi","year":"2014","journal-title":"Semin Thromb Hemost"},{"key":"10.1016\/j.ekir.2020.10.009_bib22","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1016\/j.molimm.2012.12.006","article-title":"Analysis of genetic and predisposing factors in Japanese patients with atypical hemolytic uremic syndrome","volume":"54","author":"Fan","year":"2013","journal-title":"Mol Immunol"},{"key":"10.1016\/j.ekir.2020.10.009_bib23","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1111\/ped.12549","article-title":"Atypical hemolytic uremic syndrome: Korean pediatric series","volume":"57","author":"Lee","year":"2015","journal-title":"Pediatr Int"},{"key":"10.1016\/j.ekir.2020.10.009_bib24","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.molimm.2016.01.003","article-title":"Genetic analysis and functional characterization of novel mutations in a series of patients with atypical hemolytic uremic syndrome","volume":"71","author":"Szarvas","year":"2016","journal-title":"Mol Immunol"},{"key":"10.1016\/j.ekir.2020.10.009_bib25","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1159\/000445127","article-title":"Comprehensive analysis of complement genes in patients with atypical hemolytic uremic syndrome","volume":"43","author":"Zhang","year":"2016","journal-title":"Am J Nephrol"},{"key":"10.1016\/j.ekir.2020.10.009_bib26","doi-asserted-by":"crossref","first-page":"2464","DOI":"10.4049\/jimmunol.1701695","article-title":"Statistical validation of rare complement variants provides insights into the molecular basis of atypical hemolytic uremic syndrome and C3 glomerulopathy","volume":"200","author":"Osborne","year":"2018","journal-title":"J\u00a0Immunol"},{"key":"10.1016\/j.ekir.2020.10.009_bib27","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1007\/s10157-017-1478-6","article-title":"Targeted exome sequencing in anti-factor H antibody negative HUS reveals multiple variations","volume":"22","author":"Thergaonkar","year":"2018","journal-title":"Clin Exp Nephrol"},{"key":"10.1016\/j.ekir.2020.10.009_bib28","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1016\/j.semnephrol.2013.08.003","article-title":"Atypical hemolytic uremic syndrome","volume":"33","author":"Kavanagh","year":"2013","journal-title":"Semin Nephrol"},{"key":"10.1016\/j.ekir.2020.10.009_bib29","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1681\/ASN.2009070706","article-title":"Pregnancy-associated hemolytic uremic syndrome revisited in the era of complement gene mutations","volume":"21","author":"Fakhouri","year":"2010","journal-title":"J\u00a0Am Soc Nephrol"},{"key":"10.1016\/j.ekir.2020.10.009_bib30","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1016\/j.kint.2017.07.015","article-title":"Complete functional characterization of disease-associated genetic variants in the complement factor H gene","volume":"93","author":"Merinero","year":"2018","journal-title":"Kidney Int"},{"key":"10.1016\/j.ekir.2020.10.009_bib31","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1038\/gim.2015.30","article-title":"Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology","volume":"17","author":"Richards","year":"2015","journal-title":"Genet Med"},{"key":"10.1016\/j.ekir.2020.10.009_bib32","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0060352","article-title":"Determining the population frequency of the CFHR3\/CFHR1 deletion at 1q32","volume":"8","author":"Holmes","year":"2013","journal-title":"PLoS ONE"},{"key":"10.1016\/j.ekir.2020.10.009_bib33","doi-asserted-by":"crossref","first-page":"9500","DOI":"10.1074\/jbc.M114.630871","article-title":"The major autoantibody epitope on factor H in atypical hemolytic uremic syndrome is structurally different from its homologous site in factor H-related protein 1, supporting a novel model for induction of autoimmunity in this disease","volume":"290","author":"Bhattacharjee","year":"2015","journal-title":"J\u00a0Biol Chem"},{"key":"10.1016\/j.ekir.2020.10.009_bib34","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.jim.2010.12.020","article-title":"Alternative complement pathway assessment in patients with atypical HUS","volume":"365","author":"Roumenina","year":"2011","journal-title":"J\u00a0Immunol Methods"},{"key":"10.1016\/j.ekir.2020.10.009_bib35","doi-asserted-by":"crossref","first-page":"3733","DOI":"10.1182\/blood-2013-12-547067","article-title":"Biomarkers of terminal complement activation confirm the diagnosis of aHUS and differentiate aHUS from TTP","volume":"123","author":"Cataland","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.ekir.2020.10.009_bib36","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1007\/s00467-016-3496-0","article-title":"Serological and genetic complement alterations in infection-induced and complement-mediated hemolytic uremic syndrome","volume":"32","author":"Westra","year":"2017","journal-title":"Pediatr Nephrol"},{"key":"10.1016\/j.ekir.2020.10.009_bib37","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1111\/j.1365-2141.2012.09168.x","article-title":"The use of 'real-time' complement analysis to differentiate atypical haemolytic uraemic syndrome from other forms of thrombotic microangiopathies","volume":"158","author":"Prohaszka","year":"2012","journal-title":"Br J Haematol"},{"key":"10.1016\/j.ekir.2020.10.009_bib38","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.1016\/j.mayocp.2018.07.008","article-title":"Diagnostic utility of complement serology for atypical hemolytic uremic syndrome","volume":"93","author":"Sridharan","year":"2018","journal-title":"Mayo Clin Proc"},{"key":"10.1016\/j.ekir.2020.10.009_bib39","doi-asserted-by":"crossref","first-page":"1715","DOI":"10.1182\/blood-2014-02-558296","article-title":"Dynamics of complement activation in aHUS and how to monitor eculizumab therapy","volume":"124","author":"Noris","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.ekir.2020.10.009_bib40","doi-asserted-by":"crossref","first-page":"1719","DOI":"10.2215\/CJN.05830519","article-title":"Complement activation and thrombotic microangiopathies","volume":"14","author":"Palomo","year":"2019","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.ekir.2020.10.009_bib41","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1038\/jhh.2015.112","article-title":"From malignant hypertension to hypertension-MOD: a modern definition for an old but still dangerous emergency","volume":"30","author":"Cremer","year":"2016","journal-title":"J\u00a0Hum Hypertens"},{"key":"10.1016\/j.ekir.2020.10.009_bib42","first-page":"439","article-title":"Recovery in malignant hypertension presenting as acute renal failure","volume":"53","author":"Isles","year":"1984","journal-title":"Q\u00a0J Med"},{"key":"10.1016\/j.ekir.2020.10.009_bib43","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1161\/HYPERTENSIONAHA.119.13714","article-title":"Diagnostic and risk factors for complement defects in hypertensive emergency and thrombotic microangiopathy","volume":"75","author":"Timmermans","year":"2020","journal-title":"Hypertension"},{"key":"10.1016\/j.ekir.2020.10.009_bib44","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1161\/01.HYP.0000151620.17905.ee","article-title":"Microangiopathic hemolysis and renal failure in malignant hypertension","volume":"45","author":"van den Born","year":"2005","journal-title":"Hypertension"},{"key":"10.1016\/j.ekir.2020.10.009_bib45","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1177\/0009922811412942","article-title":"Atypical hemolytic-uremic syndrome in a child presenting with malignant hypertension","volume":"52","author":"Totina","year":"2013","journal-title":"Clin Pediatr (Phila)"},{"key":"10.1016\/j.ekir.2020.10.009_bib46","doi-asserted-by":"crossref","first-page":"1420","DOI":"10.1016\/j.kint.2016.12.009","article-title":"Patients with hypertension-associated thrombotic microangiopathy may present with complement abnormalities","volume":"91","author":"Timmermans","year":"2017","journal-title":"Kidney Int"},{"key":"10.1016\/j.ekir.2020.10.009_bib47","doi-asserted-by":"crossref","first-page":"2234","DOI":"10.1681\/ASN.2018020184","article-title":"C5b9 formation on endothelial cells reflects complement defects among patients with renal thrombotic microangiopathy and severe hypertension","volume":"29","author":"Timmermans","year":"2018","journal-title":"J\u00a0Am Soc Nephrol"},{"key":"10.1016\/j.ekir.2020.10.009_bib48","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1016\/j.kint.2019.05.014","article-title":"Severe and malignant hypertension are common in primary atypical hemolytic uremic syndrome","volume":"96","author":"Cavero","year":"2019","journal-title":"Kidney Int"},{"key":"10.1016\/j.ekir.2020.10.009_bib49","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1111\/jch.12664","article-title":"Does anticomplement therapy have a role in the management of malignant hypertension?","volume":"18","author":"Tsai","year":"2016","journal-title":"J\u00a0Clin Hypertens (Greenwich)"},{"key":"10.1016\/j.ekir.2020.10.009_bib50","first-page":"446","article-title":"Hypertensive crisis and refractory hypertension caused by atypical hemolytic uremic syndrome and effect of eculizumab","volume":"34","author":"Chen","year":"2018","journal-title":"Acta Cardiol Sin"},{"key":"10.1016\/j.ekir.2020.10.009_bib51","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1182\/blood-2016-08-736579","article-title":"A\u00a0mechanistic investigation of thrombotic microangiopathy associated with IV abuse of Opana ER","volume":"129","author":"Hunt","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.ekir.2020.10.009_bib52","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1056\/NEJMoa0707330","article-title":"VEGF inhibition and renal thrombotic microangiopathy","volume":"358","author":"Eremina","year":"2008","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.ekir.2020.10.009_bib53","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1053\/j.ajkd.2017.05.023","article-title":"Quinine-induced thrombotic microangiopathy: a report of 19 patients","volume":"70","author":"Page","year":"2017","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.ekir.2020.10.009_bib54","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1182\/blood-2014-11-611335","article-title":"Drug-induced thrombotic microangiopathy: a systematic review of published reports","volume":"125","author":"Al-Nouri","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.ekir.2020.10.009_bib55","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1002\/ajh.23960","article-title":"Drug-induced thrombotic microangiopathy: experience of the Oklahoma Registry and the BloodCenter of Wisconsin","volume":"90","author":"Reese","year":"2015","journal-title":"Am J Hematol"},{"issue":"suppl 1","key":"10.1016\/j.ekir.2020.10.009_bib56","doi-asserted-by":"crossref","first-page":"S109","DOI":"10.1016\/j.nephro.2017.01.016","article-title":"Thrombotic microangiopathies and antineoplastic agents","volume":"13","author":"Grange","year":"2017","journal-title":"Nephrol Ther"},{"key":"10.1016\/j.ekir.2020.10.009_bib57","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1007\/s00280-008-0900-x","article-title":"Rituximab-based therapy for gemcitabine-induced hemolytic uremic syndrome in a patient with metastatic pancreatic adenocarcinoma: a case report","volume":"64","author":"Bharthuar","year":"2009","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1016\/j.ekir.2020.10.009_bib58","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s00280-016-3123-6","article-title":"Rituximab to treat gemcitabine-induced hemolytic-uremic syndrome (HUS) in pancreatic adenocarcinoma: a case series and literature review","volume":"79","author":"Ritchie","year":"2017","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1016\/j.ekir.2020.10.009_bib59","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1016\/j.revmed.2015.12.027","article-title":"[Clinical efficacy of eculizumab as treatment of gemcitabine-induced thrombotic microangiopathy: a case report]","volume":"37","author":"Rogier","year":"2016","journal-title":"Rev Med Interne"},{"key":"10.1016\/j.ekir.2020.10.009_bib60","doi-asserted-by":"crossref","first-page":"100","DOI":"10.5414\/CN108838","article-title":"Gemcitabine-induced hemolytic-uremic syndrome treated with eculizumab or plasmapheresis: two case reports","volume":"87","author":"Lopez Rubio","year":"2017","journal-title":"Clin Nephrol"},{"key":"10.1016\/j.ekir.2020.10.009_bib61","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1186\/s12882-018-0812-x","article-title":"The use of eculizumab in gemcitabine induced thrombotic microangiopathy","volume":"19","author":"Krishnappa","year":"2018","journal-title":"BMC Nephrol"},{"key":"10.1016\/j.ekir.2020.10.009_bib62","doi-asserted-by":"crossref","first-page":"omz048","DOI":"10.1093\/omcr\/omz048","article-title":"Eculizumab therapy in gemcitabine-induced thrombotic microangiopathy in a renal transplant recipient","volume":"2019","author":"Martin","year":"2019","journal-title":"Oxf Med Case Reports"},{"key":"10.1016\/j.ekir.2020.10.009_bib63","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1186\/s13256-017-1373-5","article-title":"Role of eculizumab in a pediatric refractory gemcitabine-induced thrombotic microangiopathy: a case report","volume":"11","author":"Facchini","year":"2017","journal-title":"J\u00a0Med Case Rep"},{"key":"10.1016\/j.ekir.2020.10.009_bib64","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1111\/bcp.13808","article-title":"Thrombotic microangiopathy associated with gemcitabine use: presentation and outcome in a national French retrospective cohort","volume":"85","author":"Daviet","year":"2019","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.ekir.2020.10.009_bib65","doi-asserted-by":"crossref","first-page":"1443","DOI":"10.1016\/j.kint.2019.01.023","article-title":"Atypical and secondary hemolytic uremic syndromes have a distinct presentation and no common genetic risk factors","volume":"95","author":"Le Clech","year":"2019","journal-title":"Kidney Int"},{"key":"10.1016\/j.ekir.2020.10.009_bib66","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1016\/j.rdc.2018.06.010","article-title":"Thrombotic microangiopathies with rheumatologic involvement","volume":"44","author":"Babar","year":"2018","journal-title":"Rheum Dis Clin North Am"},{"key":"10.1016\/j.ekir.2020.10.009_bib67","doi-asserted-by":"crossref","first-page":"2102","DOI":"10.1002\/art.40219","article-title":"The evolving landscape for complement therapeutics in rheumatic and autoimmune diseases","volume":"69","author":"Thurman","year":"2017","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.ekir.2020.10.009_bib68","first-page":"503","article-title":"Thrombotic microangiopathy and poor renal outcome in lupus patients with or without antiphospholipid syndrome","volume":"33","author":"Hernandez-Molina","year":"2015","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.ekir.2020.10.009_bib69","doi-asserted-by":"crossref","first-page":"R12","DOI":"10.1186\/ar4142","article-title":"The spectrum of renal thrombotic microangiopathy in lupus nephritis","volume":"15","author":"Song","year":"2013","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.ekir.2020.10.009_bib70","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1016\/j.semnephrol.2017.05.018","article-title":"Genetics of immune-mediated glomerular diseases: focus on complement","volume":"37","author":"Noris","year":"2017","journal-title":"Semin Nephrol"},{"key":"10.1016\/j.ekir.2020.10.009_bib71","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.semarthrit.2018.11.005","article-title":"Secondary thrombotic microangiopathy in systemic lupus erythematosus and antiphospholipid syndrome, the role of complement and use of eculizumab: case series and review of literature","volume":"49","author":"Kello","year":"2019","journal-title":"Semin Arthritis Rheum"},{"key":"10.1016\/j.ekir.2020.10.009_bib72","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jaut.2018.05.007","article-title":"The diagnosis and clinical management of the catastrophic antiphospholipid syndrome: a comprehensive review","volume":"92","author":"Cervera","year":"2018","journal-title":"J\u00a0Autoimmun"},{"key":"10.1016\/j.ekir.2020.10.009_bib73","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.3389\/fimmu.2018.01008","article-title":"Renal involvement in antiphospholipid syndrome","volume":"9","author":"Turrent-Carriles","year":"2018","journal-title":"Front Immunol"},{"key":"10.1016\/j.ekir.2020.10.009_bib74","doi-asserted-by":"crossref","first-page":"1","DOI":"10.4274\/tjh.2015.0197","article-title":"The role of complement inhibition in thrombotic angiopathies and antiphospholipid syndrome","volume":"33","author":"Erkan","year":"2016","journal-title":"Turk J Haematol"},{"key":"10.1016\/j.ekir.2020.10.009_bib75","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1007\/s10238-019-00565-8","article-title":"Eculizumab in refractory catastrophic antiphospholipid syndrome: a case report and systematic review of the literature","volume":"19","author":"Tinti","year":"2019","journal-title":"Clin Exp Med"},{"key":"10.1016\/j.ekir.2020.10.009_bib76","doi-asserted-by":"crossref","first-page":"1337","DOI":"10.1093\/rheumatology\/kew040","article-title":"Complement activation is a crucial pathogenic factor in catastrophic antiphospholipid syndrome","volume":"55","author":"Barratt-Due","year":"2016","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.ekir.2020.10.009_bib77","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1007\/s11926-015-0551-y","article-title":"Recent developments in the classification, evaluation, pathophysiology, and management of scleroderma renal crisis","volume":"18","author":"Ghossein","year":"2016","journal-title":"Curr Rheumatol Rep"},{"key":"10.1016\/j.ekir.2020.10.009_bib78","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1038\/nrneph.2016.124","article-title":"Scleroderma renal crisis and renal involvement in systemic sclerosis","volume":"12","author":"Woodworth","year":"2016","journal-title":"Nat Rev Nephrol"},{"key":"10.1016\/j.ekir.2020.10.009_bib79","doi-asserted-by":"crossref","first-page":"441","DOI":"10.2169\/internalmedicine.1441-18","article-title":"Scleroderma renal crisis complicated with thrombotic microangiopathy triggered by influenza B virus infection","volume":"58","author":"Shimizu","year":"2019","journal-title":"Intern Med"},{"key":"10.1016\/j.ekir.2020.10.009_bib80","doi-asserted-by":"crossref","first-page":"1040","DOI":"10.3899\/jrheum.131210","article-title":"Scleroderma renal crisis","volume":"41","author":"Mouthon","year":"2014","journal-title":"J\u00a0Rheumatol"},{"key":"10.1016\/j.ekir.2020.10.009_bib81","doi-asserted-by":"crossref","first-page":"293","DOI":"10.5414\/CN107465","article-title":"Differentiating scleroderma renal crisis from other causes of thrombotic microangiopathy in a postpartum patient","volume":"80","author":"Abudiab","year":"2013","journal-title":"Clin Nephrol"},{"key":"10.1016\/j.ekir.2020.10.009_bib82","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1016\/j.humpath.2008.08.001","article-title":"Renal biopsy findings predicting outcome in scleroderma renal crisis","volume":"40","author":"Batal","year":"2009","journal-title":"Hum Pathol"},{"key":"10.1016\/j.ekir.2020.10.009_bib83","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1186\/s13075-016-1168-x","article-title":"Analysis of complement biomarkers in systemic sclerosis indicates a distinct pattern in scleroderma renal crisis","volume":"18","author":"Okroj","year":"2016","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.ekir.2020.10.009_bib84","first-page":"6051083","article-title":"Scleroderma renal crisis debute with thrombotic microangiopathy: a successful case treated with eculizumab","volume":"2018","author":"Uriarte","year":"2018","journal-title":"Case Rep Nephrol"},{"key":"10.1016\/j.ekir.2020.10.009_bib85","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1093\/ckj\/sfv101","article-title":"Eculizumab for rescue of thrombotic microangiopathy in PM-Scl antibody-positive autoimmune overlap syndrome","volume":"8","author":"Thomas","year":"2015","journal-title":"Clin Kidney J"},{"key":"10.1016\/j.ekir.2020.10.009_bib86","doi-asserted-by":"crossref","first-page":"e4459","DOI":"10.1097\/MD.0000000000004459","article-title":"Complement activation and effect of eculizumab in scleroderma renal crisis","volume":"95","author":"Devresse","year":"2016","journal-title":"Medicine (Baltimore)"},{"key":"10.1016\/j.ekir.2020.10.009_bib87","doi-asserted-by":"crossref","first-page":"2100","DOI":"10.2215\/CJN.13121211","article-title":"Obstetric nephrology: AKI and thrombotic microangiopathies in pregnancy","volume":"7","author":"Fakhouri","year":"2012","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.ekir.2020.10.009_bib88","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1053\/j.ackd.2020.01.002","article-title":"Complement-mediated disorders in pregnancy","volume":"27","author":"Amari Chinchilla","year":"2020","journal-title":"Adv Chronic Kidney Dis"},{"issue":"11","key":"10.1016\/j.ekir.2020.10.009_bib89","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0233199","article-title":"Evidences of histologic thrombotic microangiopathy and the impact in renal outcomes of patients with IgA nephropathy","volume":"15","author":"Neves","year":"2020","journal-title":"PLoS One"},{"key":"10.1016\/j.ekir.2020.10.009_bib90","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1681\/ASN.2010111130","article-title":"A\u00a0clinicopathologic study of thrombotic microangiopathy in IgA nephropathy","volume":"23","author":"El Karoui","year":"2012","journal-title":"J\u00a0Am Soc Nephrol"},{"key":"10.1016\/j.ekir.2020.10.009_bib91","doi-asserted-by":"crossref","first-page":"1405","DOI":"10.1016\/j.molimm.2008.12.002","article-title":"Is complement factor H a susceptibility factor for IgA nephropathy?","volume":"46","author":"Edey","year":"2009","journal-title":"Mol Immunol"},{"key":"10.1016\/j.ekir.2020.10.009_bib92","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1055\/s-0034-1376153","article-title":"Spectrum of complement-mediated thrombotic microangiopathies: pathogenetic insights identifying novel treatment approaches","volume":"40","author":"Riedl","year":"2014","journal-title":"Semin Thromb Hemost"},{"key":"10.1016\/j.ekir.2020.10.009_bib93","doi-asserted-by":"crossref","first-page":"337","DOI":"10.3389\/fimmu.2019.00337","article-title":"Complement in thrombotic microangiopathies: unraveling Ariadne\u2019s thread into the labyrinth of complement therapeutics","volume":"10","author":"Gavriilaki","year":"2019","journal-title":"Front Immunol"},{"key":"10.1016\/j.ekir.2020.10.009_bib94","doi-asserted-by":"crossref","DOI":"10.1136\/bcr-2017-222582","article-title":"Thrombotic microangiopathy associated with Mycoplasma pneumoniae infection","volume":"2018","author":"Caeiro Alves","year":"2018","journal-title":"BMJ Case Rep"},{"key":"10.1016\/j.ekir.2020.10.009_bib95","doi-asserted-by":"crossref","DOI":"10.1111\/tid.13305","article-title":"Ehrlichiosis infection mimicking thrombotic microangiopathy syndrome early after kidney transplantation","author":"Hassan","year":"2020","journal-title":"Transpl Infect Dis"},{"key":"10.1016\/j.ekir.2020.10.009_bib96","doi-asserted-by":"crossref","first-page":"2426","DOI":"10.1111\/trf.14829","article-title":"Secondary thrombotic microangiopathy with severely reduced ADAMTS13 activity in a patient with Capnocytophaga canimorsus sepsis: a case report","volume":"58","author":"Smeets","year":"2018","journal-title":"Transfusion"},{"key":"10.1016\/j.ekir.2020.10.009_bib97","doi-asserted-by":"crossref","first-page":"3479","DOI":"10.2169\/internalmedicine.3110-19","article-title":"An immunocompetent case of Capnocytophaga canimorsus infection complicated by secondary thrombotic microangiopathy and disseminated intravascular coagulation","volume":"58","author":"Tani","year":"2019","journal-title":"Intern Med"},{"key":"10.1016\/j.ekir.2020.10.009_bib98","doi-asserted-by":"crossref","first-page":"960","DOI":"10.4103\/1319-2442.265474","article-title":"Acute kidney injury due to acute cortical necrosis following vivax malaria","volume":"30","author":"Nair","year":"2019","journal-title":"Saudi J Kidney Dis Transpl"},{"key":"10.1016\/j.ekir.2020.10.009_bib99","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1080\/15563650.2018.1510129","article-title":"Acute kidney injury induced by thrombotic microangiopathy in two cases of Bothrops envenomation","volume":"57","author":"Malaque","year":"2019","journal-title":"Clin Toxicol (Phila)"},{"key":"10.1016\/j.ekir.2020.10.009_bib100","doi-asserted-by":"crossref","first-page":"321","DOI":"10.4103\/0971-4065.202837","article-title":"Dengue fever\u2013induced thrombotic microangiopathy: an unusual cause of renal failure","volume":"27","author":"Bhargava","year":"2017","journal-title":"Indian J Nephrol"},{"key":"10.1016\/j.ekir.2020.10.009_bib101","doi-asserted-by":"crossref","DOI":"10.1111\/tid.12824","article-title":"Successful treatment of thrombotic microangiopathy associated with dengue infection: a case report and literature review","volume":"20","author":"Nieto-Rios","year":"2018","journal-title":"Transpl Infect Dis"},{"key":"10.1016\/j.ekir.2020.10.009_bib102","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1080\/20469047.2019.1706299","article-title":"Thrombotic thrombocytopenic purpura in a 2.5-year-old boy with dengue infection: a rare complication","volume":"40","author":"Gogireddy","year":"2020","journal-title":"Paediatr Int Child Health"},{"key":"10.1016\/j.ekir.2020.10.009_bib103","doi-asserted-by":"crossref","first-page":"385","DOI":"10.6002\/ect.2018.0107","article-title":"Delayed diagnosis of West Nile virus infection in a kidney transplant patient due to inaccuracies in commonly available diagnostic tests","volume":"18","author":"Zanoni","year":"2020","journal-title":"Exp Clin Transplant"},{"key":"10.1016\/j.ekir.2020.10.009_bib104","doi-asserted-by":"crossref","DOI":"10.1093\/jtm\/tax028","article-title":"Fatal case of chikungunya and concomitant thrombotic thrombocytopenic purpura in French Guiana during air flight medical evacuation","volume":"24","author":"Epelboin","year":"2017","journal-title":"J\u00a0Travel Med"},{"key":"10.1016\/j.ekir.2020.10.009_bib105","first-page":"96","article-title":"Chikungunya fever presenting as life threatening thrombotic thrombocytopenic purpura","volume":"65","author":"Kumar","year":"2017","journal-title":"J\u00a0Assoc Physicians India"},{"key":"10.1016\/j.ekir.2020.10.009_bib106","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1002\/jca.21673","article-title":"Thrombotic thrombocytopenic purpura: a 5-year tertiary care centre experience","volume":"34","author":"Swart","year":"2019","journal-title":"J\u00a0Clin Apher"},{"key":"10.1016\/j.ekir.2020.10.009_bib107","doi-asserted-by":"crossref","first-page":"2009","DOI":"10.1007\/s00467-017-3783-4","article-title":"Influenza-associated thrombotic microangiopathies","volume":"33","author":"Bitzan","year":"2018","journal-title":"Pediatr Nephrol"},{"key":"10.1016\/j.ekir.2020.10.009_bib108","doi-asserted-by":"crossref","first-page":"F454","DOI":"10.1152\/ajprenal.00376.2017","article-title":"Advances in our understanding of the pathogenesis of hemolytic uremic syndromes","volume":"314","author":"Bowen","year":"2018","journal-title":"Am J Physiol Renal Physiol"},{"key":"10.1016\/j.ekir.2020.10.009_bib109","doi-asserted-by":"crossref","first-page":"2561","DOI":"10.1056\/NEJMc1100859","article-title":"Eculizumab in severe Shiga-toxin-associated HUS","volume":"364","author":"Lapeyraque","year":"2011","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.ekir.2020.10.009_bib110","doi-asserted-by":"crossref","DOI":"10.1128\/mBio.01753-18","article-title":"Complement activation contributes to severe acute respiratory syndrome coronavirus pathogenesis","volume":"9","author":"Gralinski","year":"2018","journal-title":"mBio"},{"key":"10.1016\/j.ekir.2020.10.009_bib111","doi-asserted-by":"crossref","DOI":"10.1021\/acs.jproteome.0c00365","article-title":"Serum proteomics in COVID-19 patients: altered coagulation and complement status as a function of IL-6 level","author":"D\u2019Alessandro","year":"2020","journal-title":"J\u00a0Proteome Res"},{"key":"10.1016\/j.ekir.2020.10.009_bib112","first-page":"4417","article-title":"The case of complement activation in COVID-19 multiorgan impact","volume":"19","author":"Noris","year":"2020","journal-title":"Kidney Int"},{"key":"10.1016\/j.ekir.2020.10.009_bib113","doi-asserted-by":"crossref","first-page":"P681","DOI":"10.1016\/S2213-2600(20)30243-5","article-title":"Pulmonary and cardiac pathology in African American patients with COVID-19: an autopsy series from New Orleans","volume":"8","author":"Fox","year":"2020","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.ekir.2020.10.009_bib114","doi-asserted-by":"crossref","DOI":"10.4049\/jimmunol.2000644","article-title":"COVID-19: complement, coagulation, and collateral damage","author":"Lo","year":"2020","journal-title":"J\u00a0Immunol"},{"key":"10.1016\/j.ekir.2020.10.009_bib115","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1016\/j.kint.2020.05.025","article-title":"Thrombotic microangiopathy in a patient with COVID-19","volume":"98","author":"Jhaveri","year":"2020","journal-title":"Kidney Int"},{"key":"10.1016\/j.ekir.2020.10.009_bib116","doi-asserted-by":"crossref","first-page":"e38","DOI":"10.1056\/NEJMc2007575","article-title":"Coagulopathy and antiphospholipid antibodies in patients with Covid-19","volume":"382","author":"Zhang","year":"2020","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.ekir.2020.10.009_bib117","first-page":"4040","article-title":"Eculizumab treatment in patients with COVID-19: preliminary results from real life ASL Napoli 2 Nord experience","volume":"24","author":"Diurno","year":"2020","journal-title":"Eur Rev Med Pharmacol Sci"},{"key":"10.1016\/j.ekir.2020.10.009_bib118","doi-asserted-by":"crossref","first-page":"e63","DOI":"10.1097\/MPH.0000000000001180","article-title":"Steroid responsive atypical hemolytic uremic syndrome triggered by influenza B infection","volume":"41","author":"Mittal","year":"2019","journal-title":"J\u00a0Pediatr Hematol Oncol"},{"key":"10.1016\/j.ekir.2020.10.009_bib119","first-page":"178","article-title":"[Atypical hemolytic uremic syndrome with C3 p.I1157T missense mutation successfully treated with eculizumab]","volume":"59","author":"Okano","year":"2018","journal-title":"Rinsho Ketsueki"},{"key":"10.1016\/j.ekir.2020.10.009_bib120","first-page":"797","article-title":"A\u00a0case of suspected Streptococcus pneumoniae hemolytic uremic syndrome (pHUS) with utilization of minor crossmatching for platelet blood products lead to a diagnosis of atypical hemolytic uremic syndrome (aHUS)","volume":"48","author":"Tong","year":"2018","journal-title":"Ann Clin Lab Sci"},{"key":"10.1016\/j.ekir.2020.10.009_bib121","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1007\/s00467-001-0798-6","article-title":"Hemolytic uremic syndrome due to an altered factor H triggered by neonatal pertussis","volume":"17","author":"Berner","year":"2002","journal-title":"Pediatr Nephrol"},{"key":"10.1016\/j.ekir.2020.10.009_bib122","doi-asserted-by":"crossref","first-page":"1210","DOI":"10.1097\/INF.0b013e31826153fb","article-title":"Atypical hemolytic uremic syndrome associated with Bordetella pertussis infection","volume":"31","author":"Obando","year":"2012","journal-title":"Pediatr Infect Dis J"},{"key":"10.1016\/j.ekir.2020.10.009_bib123","doi-asserted-by":"crossref","first-page":"2752","DOI":"10.1093\/ndt\/gfp166","article-title":"Varicella as a trigger of atypical haemolytic uraemic syndrome associated with complement dysfunction: two cases","volume":"24","author":"Kwon","year":"2009","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.ekir.2020.10.009_bib124","doi-asserted-by":"crossref","first-page":"540","DOI":"10.4103\/1319-2442.256865","article-title":"Complement factor H gene polymorphisms and vivax malaria associated thrombotic microangiopathy","volume":"30","author":"Agrawal","year":"2019","journal-title":"Saudi J Kidney Dis Transpl"},{"key":"10.1016\/j.ekir.2020.10.009_bib125","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1080\/20469047.2019.1616458","article-title":"CFH and CFB mutations in Shiga toxin-associated haemolytic uraemic syndrome in a 6-year-old boy","volume":"40","author":"Celakil","year":"2020","journal-title":"Paediatr Int Child Health"},{"key":"10.1016\/j.ekir.2020.10.009_bib126","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1111\/jpc.14685","article-title":"Follow-up of children with infection-associated haemolytic uraemic syndrome 1979\u20131995: would eculizumab have improved prognosis?","volume":"56","author":"Aldridge","year":"2020","journal-title":"J\u00a0Paediatr Child Health"},{"key":"10.1016\/j.ekir.2020.10.009_bib127","doi-asserted-by":"crossref","first-page":"364","DOI":"10.2215\/CJN.05830518","article-title":"Complement gene variants and Shiga toxin-producing Escherichia coli-associated hemolytic uremic syndrome: retrospective genetic and clinical study","volume":"14","author":"Fremeaux-Bacchi","year":"2019","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.ekir.2020.10.009_bib128","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1093\/ckj\/sfx030","article-title":"Rare genetic variants in Shiga toxin-associated haemolytic uraemic syndrome: genetic analysis prior to transplantation is essential","volume":"10","author":"Dowen","year":"2017","journal-title":"Clin Kidney J"},{"key":"10.1016\/j.ekir.2020.10.009_bib129","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1016\/j.kint.2018.01.037","article-title":"C3 glomerulopathy associated with monoclonal Ig is a distinct subtype","volume":"94","author":"Ravindran","year":"2018","journal-title":"Kidney Int"},{"key":"10.1016\/j.ekir.2020.10.009_bib130","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1016\/j.kint.2016.09.045","article-title":"Thrombotic microangiopathy associated with monoclonal gammopathy","volume":"91","author":"Ravindran","year":"2017","journal-title":"Kidney Int"}],"container-title":["Kidney International Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2468024920316478?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2468024920316478?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T03:34:27Z","timestamp":1762832067000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2468024920316478"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,1]]},"references-count":130,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,1]]}},"alternative-id":["S2468024920316478"],"URL":"https:\/\/doi.org\/10.1016\/j.ekir.2020.10.009","relation":{},"ISSN":["2468-0249"],"issn-type":[{"value":"2468-0249","type":"print"}],"subject":[],"published":{"date-parts":[[2021,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Complement in Secondary Thrombotic Microangiopathy","name":"articletitle","label":"Article Title"},{"value":"Kidney International Reports","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ekir.2020.10.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 International Society of Nephrology. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}